Implications of early diagnosis of autosomal dominant polycystic kidney disease: A post hoc analysis of the TEMPO 3:4 trial.

Janssens, Peter; Jouret, François; Bammens, Bert; Liebau, Max C.; Schaefer, Franz; Dandurand, Ann; Perrone, Ronald D.; Muller, Roman-Ulrich; Pao, Christina S.; Mekahli, Djalila

doi:10.1038/s41598-020-61303-9

Article (Scientific journals)

Implications of early diagnosis of autosomal dominant polycystic kidney disease: A post hoc analysis of the TEMPO 3:4 trial.

Janssens, Peter; Jouret, François; Bammens, Bert et al.

2020 • In Scientific Reports, 10 (1), p. 4294

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/246072

DOI
10.1038/s41598-020-61303-9

PubMed
32152377

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

s41598-020-61303-9.pdf

Publisher postprint (1.24 MB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Abstract :

[en] It is unknown whether early diagnosis of autosomal dominant polycystic kidney disease (ADPKD) can enable earlier management and improve outcomes. We conducted a post hoc analysis of data from the TEMPO 3:4 trial. Subjects were stratified by ADPKD diagnosis at age </=18 (childhood diagnosis [CD]) or>18 (adulthood diagnosis [AD]). Groups were compared for baseline characteristics and total kidney volume (TKV) growth and estimated glomerular filtration rate (eGFR) decline over 3 years. 294 CD and 1148 AD subjects were analyzed. At inclusion, CD subjects were younger (mean age 34.2 versus 39.8 years; p < 0.0001) and had better eGFR (mean +/- SD 87.4 +/- 23.9 versus 80.1 +/- 20.7 mL/min/1.73 m(2); p < 0.0001), while CD had more severe Mayo risk classification (p < 0.0001) and more PKD1 mutations (p = 0.003). No statistical differences were found in TKV or eGFR change. At study end, placebo-treated CD subjects had better eGFR than projected by a prediction equation (mean difference +/-SD for observed versus predicted eGFR: 2.18 +/- 10.7 mL/min/1.73 m(2); p = 0.0475). However, these results are not confirmed when excluding stage 1 CKD. Whether CD subjects, despite their risk profile, have a slower disease course than predicted remains inconclusive. Future studies are needed to confirm that early diagnosis and management can alter the disease course of ADPKD.

Disciplines :

Pediatrics

Author, co-author :

Janssens, Peter

Jouret, François ; Université de Liège - ULiège > Cardiovascular Sc.-Lab. of Translational Res. in Nephrology

Bammens, Bert

Liebau, Max C.

Schaefer, Franz

Dandurand, Ann

Perrone, Ronald D.

Muller, Roman-Ulrich

Pao, Christina S.

Mekahli, Djalila

Language :

English

Title :

Implications of early diagnosis of autosomal dominant polycystic kidney disease: A post hoc analysis of the TEMPO 3:4 trial.

Publication date :

2020

Journal title :

Scientific Reports

eISSN :

2045-2322

Publisher :

Nature Publishing Group, London, United Kingdom

Volume :

Issue :

Pages :

4294

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 18 March 2020

Statistics

Number of views

75 (5 by ULiège)

Number of downloads

61 (5 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Chebib, F. T. & Torres, V. E. Autosomal dominant polycystic kidney disease: core curriculum 2016. Am. J. Kidney Dis. 67, 792–810 (2016).
Grantham, J. J. et al. Determinants of renal volume in autosomal-dominant polycystic kidney disease. Kidney Int. 73, 108–116 (2008).
De Rechter, S. et al. Clinicians’ attitude towards family planning and timing of diagnosis in autosomal dominant polycystic kidney disease. Plos One. 12, e0185779 (2017).
Torres, V. E. Pro: tolvaptan delays the progression of autosomal dominant polycystic kidney disease. Nephrol. Dial. Transplant. 34, 30–34 (2019).
Schrier, R. W. et al. Blood pressure in early autosomal dominant polycystic kidney disease. N. Engl. J. Med. 371, 2255–2266 (2014).
Torres, V. E. et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 367, 2407–2418 (2012).
Torres, V. E. et al. Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial. Nephrol. Dial. Transplant. 33, 477–489 (2018).
Torres, V. E. et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N. Engl. J. Med. 377, 1930–1942 (2017).
Edwards, M. E. et al. Long-term administration of tolvaptan in autosomal dominant polycystic kidney disease. Clin. J. Am. Soc. Nephrol. 13, 1153–1161 (2018).
De Rechter, S., Bammens, B., Schaefer, F., Liebau, M. C. & Mekahli, D. Unmet needs and challenges for follow-up and treatment of autosomal dominant polycystic kidney disease: the paediatric perspective. Clin. Kidney J. 11(Suppl 1), i14–i26 (2018).
De Rechter, S. et al. ADPedKD: a global online platform on the management of children with ADPKD. Kidney Int. Rep. 4, 1271–1284 (2019).
Gimpel, C. et al. International consensus statement on the diagnosis and management of autosomal dominant polycystic kidney disease in children and young people. Nat. Rev. Nephrol. 15, 713–726 (2019).
Torres, V. E. et al. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study. Am. J. Kidney Dis. 57, 692–699 (2011).
Levey, A. S. et al. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150, 604–612 (2009).
Horio, M., Imai, E., Yasuda, Y., Watanabe, T. & Matsuo, S. Modification of the CKD epidemiology collaboration (CKD-EPI) equation for Japanese: accuracy and use for population estimates. Am. J. Kidney Dis. 56, 32–38 (2010).
Irazabal, M. V. et al. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J. Am. Soc. Nephrol. 26, 160–172 (2015).
Yu, A. S. L. et al. Long-term trajectory of kidney function in autosomal-dominant polycystic kidney disease. Kidney Int. 95, 1253–1261 (2019).
Helal, I. et al. Glomerular hyperfiltration and renal progression in children with autosomal dominant polycystic kidney disease. Clin. J. Am. Soc. Nephrol. 6, 2439–2443 (2011).
Helal, I., Fick-Brosnahan, G. M., Reed-Gitomer, B. & Schrier, R. W. Glomerular hyperfiltration: definitions, mechanisms and clinical implications. Nat. Rev. Nephrol. 8, 293–300 (2012).
Messchendorp, A. L. et al. Kidney function reserve capacity in early and later stage autosomal dominant polycystic kidney disease. Clin. J. Am. Soc. Nephrol. 13, 1680–1692 (2018).
Grantham, J. J. & Torres, V. E. The importance of total kidney volume in evaluating progression of polycystic kidney disease. Nat. Rev. Nephrol. 12, 667–677 (2016).
Chapman, A. B. et al. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin. J. Am. Soc. Nephrol. 7, 479–486 (2012).
Cornec-Le Gall, E. et al. The PROPKD score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 27, 942–951 (2016).
Cornec-Le Gall, E., Audrézet, M. P., Le Meur, Y., Chen, J. M. & Férec, C. Genetics and pathogenesis of autosomal dominant polycystic kidney disease: 20 years on. Hum. Mutat. 35, 1393–1406 (2014).
Bergmann, C. ARPKD and early manifestations of ADPKD: the original polycystic kidney disease and phenocopies. Pediatr. Nephrol. 30, 15–30 (2015).
Groopman, E. E. et al. Diagnostic utility of exome sequencing for kidney disease. N. Engl. J. Med. 380, 142–151 (2019).
Grantham, J. J. Rationale for early treatment of polycystic kidney disease. Pediatr. Nephrol. 30, 1053–1062 (2015).
Shalev, H., Romanovsky, I., Knoers, N. V., Lupa, S. & Landau, D. Bladder function impairment in aquaporin-2 defective nephrogenic diabetes insipidus. Nephrol. Dial. Transplant. 19, 608–613 (2004).